MICA: A phase II trial examining Bermekimab (anti-IL1 alpha) effects on muscle, physical function and appetite, in lung, pancreatic or ovarian cancer

Project Details

StatusActive
Effective start/end date1/06/1930/11/21

Funding

  • MRC: £338,804.00